250 related articles for article (PubMed ID: 21693025)
1. Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients.
Bosch E; Ezcurra D
Reprod Biol Endocrinol; 2011 Jun; 9():82. PubMed ID: 21693025
[TBL] [Abstract][Full Text] [Related]
2. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
4. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
[TBL] [Abstract][Full Text] [Related]
5. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
6. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].
Wu CX; Zhang T; Shu L; Huang J; Diao FY; Ding W; Gao Y; Wang W; Mao YD; Cui YG; Liu JY
Zhonghua Fu Chan Ke Za Zhi; 2018 Mar; 53(3):160-166. PubMed ID: 29609229
[No Abstract] [Full Text] [Related]
7. Outcomes of anti-Müllerian hormone-tailored ovarian stimulation protocols in in vitro fertilization/intracytoplasmic sperm injection cycles in women of advanced age.
Liao CC; Lee RK; Lin SY; Lin MH; Hwu YM
Taiwan J Obstet Gynecol; 2016 Apr; 55(2):239-43. PubMed ID: 27125408
[TBL] [Abstract][Full Text] [Related]
8. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
[TBL] [Abstract][Full Text] [Related]
9. Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols.
Alviggi C; Humaidan P; Ezcurra D
Reprod Biol Endocrinol; 2012 Feb; 10():9. PubMed ID: 22309877
[TBL] [Abstract][Full Text] [Related]
10. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study.
Weigert M; Krischker U; Pöhl M; Poschalko G; Kindermann C; Feichtinger W
Fertil Steril; 2002 Jul; 78(1):34-9. PubMed ID: 12095487
[TBL] [Abstract][Full Text] [Related]
11. Maternal serum concentration of anti-Müllerian hormone is a better predictor than basal follicle stimulating hormone of successful blastocysts development during IVF treatment.
Sadruddin S; Barnett B; Ku L; Havemann D; Mucowski S; Herrington R; Burggren W
PLoS One; 2020; 15(10):e0239779. PubMed ID: 33044971
[TBL] [Abstract][Full Text] [Related]
12. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
[TBL] [Abstract][Full Text] [Related]
14. Anti-Müllerian hormone is correlated with cumulative live birth in minimal ovarian stimulation with clomiphene citrate: a retrospective cohort study.
Ezoe K; Ni X; Kobayashi T; Kato K
BMC Pregnancy Childbirth; 2020 Nov; 20(1):740. PubMed ID: 33246461
[TBL] [Abstract][Full Text] [Related]
15. Determination of the efficiency of controlled ovarian hyperstimulation in the gonadotropin-releasing hormone agonist-suppression cycle using the initial follicle count during gonadotropin stimulation.
Huang FJ; Chang SY; Tsai MY; Kung FT; Wu JF; Chang HW
J Assist Reprod Genet; 2001 Feb; 18(2):91-6. PubMed ID: 11285987
[TBL] [Abstract][Full Text] [Related]
16. Oocyte matched follicular fluid anti-Müllerian hormone is an excellent predictor of live birth after fresh single embryo transfer.
Ciepiela P; Dulęba AJ; Kario A; Chełstowski K; Branecka-Woźniak D; Kurzawa R
Hum Reprod; 2019 Nov; 34(11):2244-2253. PubMed ID: 31725884
[TBL] [Abstract][Full Text] [Related]
17. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
[TBL] [Abstract][Full Text] [Related]
19. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin-releasing hormone agonist and antagonists, on follicular fluid stem cell factor and serum urocortin 1 levels on the day of oocyte retrieval.
Celik O; Celik E; Yilmaz E; Celik N; Turkcuoglu I; Ulas M; Kumbak B; Aktan E; Ozerol I
Arch Gynecol Obstet; 2013 Dec; 288(6):1417-22. PubMed ID: 23801011
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
